Introduction
An isotope dilution liquid chromatography/tandem mass spectrometry (ID-LC/MS/MS) is proposed as a reference method to determine the level of tyrosine in serum. The advantages of ID-LC/MS/MS include simple sample preparation without the need for derivatization, the selective detection of compounds of interest in complex matrices, and the use of an isotopically labeled analogue as an internal standard. The transformation of the analyte during sample preparation can be compensated by the use of an isotopically labeled analogue as an internal standard. Once equilibration of the spike and analyte have been achieved, the total recovery of the analyte is not required, as the determined value is based on the measurement of the ratio between the analyte and the isotopically labeled analogue. The clinical significance of a tyrosine measurement in serum is linked to an early diagnosis of tyrosinemia, an inborn error of metabolism. Tyrosinemia increases the tyrosine concentration in blood due to an error in tyrosine metabolism. It has several forms; type I and type II tyrosinemia are included among them. Type I tyrosinemia shows increased tyrosine levels in blood and urine, elevated methionine levels in blood, and excretion of a large amount of dihydroxyphenylalanine (DOPA) and other tyrosine metabolites in urine due to a lack of the fumarylacetoacetate hydrolase or p-hydroxyphenyl-pyruvic acid (PHPPA) oxidase. The primary effects of the disease are damage to the liver and kidneys. Type II tyrosinemia is a deficiency of the hepatic enzyme tyrosine aminotransferase, which catalyzes the first stage of tyrosine catabolism. It can cause eye lesions, such as corneal erosions, and skin lesions of the palms and soles. [1] [2] [3] The upper limit of tyrosine in blood is 8 mg/dL. Tyrosinemia is a rare disease, affecting only 1 out of 100000 people. However, tyrosine is an important target material in neonatal screening, as tyrosinemia can be cured through drug and diet treatments when it is diagnosed early. [4] [5] [6] [7] [8] [9] [10] Tyrosine determination for newborn screening in clinics is feasible by various methods: the Guthrie test, enzyme immunoassay (EIA), HPLC, and through tandem mass spectrometry. Currently, tandem mass spectrometry, which offers simplicity, accuracy and speed of measurement, is used widely. [11] [12] [13] [14] [15] [16] [17] [18] The blood samples of patients found from newborn screening are retested by HPLC in order to verify the results. However, a number of tests from different clinics have generated inconsistent results. 19 To resolve this problem, the Joint Committee on Traceability in Laboratory Medicine (JCTLM) recommends that clinics make their measurement results traced to the International System of Units (SI). Isotope dilution mass spectrometry (IDMS) is regarded as a reference method for organic compounds, as it causes the measurement results to be traced to SI units without significant empirical correction factors. 20, 21 For this reason, the ID-LC/MS/MS method was applied here to determine the level of tyrosine in human serum. The expanded uncertainty was evaluated according to the ISO guide, and the degrees of contribution of each uncertainty parameter were also checked. The serum tyrosine was also determined by clinical laboratories in Korea, and the results were compared with the present ID-LC/MS/MS results. In order to verify the proposed method, the standard reference material 2389 (amino acids in 0.1 N HCl) of the National Institute of Standards and Technology (NIST) with a value certified by HPLC was analyzed.
Experimental

Materials
Pure tyrosine (99+%) was purchased from Aldrich. An isotopically labeled analogue, 4-hydroxyphenyl-13 C6-alanine (99+%), was purchased from Cambridge Isotope Laboratories Inc. (Andover, MA, USA). Acetonitrile (HPLC grade) and methanol (HPLC grade) were purchased from Merck, and acetic acid (99.9%) and hydrochloric acid (99.999%) were purchased from Aldrich. Pure water was prepared through the use of a Millipore alpha Q purification system and further distillation. The mobile phase was filtered with a 0.22 μm PVDF filter (Supelco) before use.
SRM 2389 was purchased from NIST. The human serum pool, which was confirmed as negative through HBV, HCV and V.D.S. testing, was obtained from Seoul Clinical Laboratory. The serum was filtered with 0.2 μm filter (sterilized, Millipore) to remove solid materials such as proteins, lipids and any microorganisms. It was distributed into 3 mL sterilized polypropylene vials, termed a KRISS serum, and stored in a deep freezer at -70˚C. The serum vials for this study were randomly selected from the serum batch.
Standard solution
Four independent 15 μg/g tyrosine standard solutions were gravimetrically prepared in 0.1 N HCl, due to its low solubility, using a micro balance (Mettler Toledo, 2 g) and an analytical balance (Mettler Toledo, 205 g). 4-Hydroxyphenyl-13 C6-alanine standards (15 μg/g) were also prepared gravimetrically in water and 0.1 N HCl. For each of the 4 tyrosine standard solutions, the weighted aliquots of tyrosine standard solutions were mixed with the weighted aliquots of a 4-hydroxyphenyl-13 C6-alanine standard solution to prepare 4 calibration blends, having a tyrosine/4-hydroxyphenyl-13 C6-alanine weight ratios of 1. The 4 calibration blends were diluted with a mobile phase to a level of 0.5 μg/g, which is the optimum concentration for LC/MS/MS measurements. The self-consistency of the standard solutions and the calibration blends was verified by comparisons with their peak areas and their weight ratios. Each preparation as well as verification of each standard solution and the calibration blends were independently carried out for every measurement.
Sample preparation
In order to determine the amount of isotopically labeled analogue solution to add to the serum, we made an initial estimate of the tyrosine concentration in the serum through preliminary tests. 21 In the preliminary test, 4-hydroxyphenyl-13 C6-alanine solution was added to the serum in order to match at the upper limit of tyrosine in blood, 8 mg/dL. The serum was also checked for isotopic interferences. The frozen human serum bottles and required apparatuses were left in a weighing room for 2 h to allow for equilibration of the temperature. A 1-mL volume of a serum sample was taken in a 4 mL vial, and the serum was spiked with the 4-hydroxyphenyl-13 C6-alanine standard solution to match the estimated concentration of tyrosine in the serum.
The exact amounts of serum and the 4-hydroxyphenyl-13 C6-alanine solution taken into the vial were determined by weighing the vial before and after the addition of each of the solutions into the vial.
The spiked serum was mixed well and slowly swirled for equilibration for 2 h. Following this, the serum was transferred to a 15 mL Falcon tube, and 5 mL of acetonitrile was added to the tube in order to precipitate the proteins. After centrifugation for 10 min at 4000 rpm, the supernatant was transferred into a Zymark tube and evaporated to 1 mL under a stream of nitrogen at room temperature. The serum sample was diluted with a mobile phase to a level of 0.5 μg/g, and was filtered with a 0.22 μm PVDF syringe filter.
The NIST SRM was approximately diluted to 100 μg/g with water, and the exact concentration was calculated. One milliliter of diluted SRM was put into a 4 mL vial and spiked with the 4-hydroxyphenyl-13 C6-alanine standard solution to match the tyrosine concentration of the sample. The solution was diluted with a mobile phase to a 0.5 μg/g concentration before analysis.
LC/tandem mass spectrometry conditions
The LC/MS/MS used in this study was a triple-stage quadrupole mass spectrometer, API 2000 MS/MS (ABI, USA), connected to an Agilent 1100 HPLC (HP, USA) through a turboelectrospray ionization interface. The LC conditions were as follows: a Thermo BDS Hypersil C18 (150 × 3 mm, 5 μm) column connected to a C18 guard cartridge was utilized. The column was kept at room temperature during the chromatographic run. The mobile phase was 0.1% acetic acid (water 1:methanol 1, v/v). The flow rate was 0.25 mL/min, and the sample volume was 10 μL.
Tuning was carried out in the electrospray positive ionization mode with the blend of tyrosine and 4-hydroxyphenyl-13 C6-alanine at 1 μg/g. In the selected ion monitoring (SIM) mode, molecular ions of tyrosine and 4-hydroxyphenyl- 13 The optimum conditions were selected as follows: the curtain gas, 14 psi; the collision gas, 4 psi; the ionspray voltage, 5500 V; the temperature, 350˚C; the ion source gas-1, 70 psi; the ion source gas-2, 70 psi; the collision energy, 20 V.
Measurement protocol
First, an initial estimate of the tyrosine concentration in the serum was made and the isotopic interferences were checked. In order to check the interferences, we analyzed pure tyrosine solution, 4-hydroxyphenyl-13 C6-alanine solution and serum under LC/MS/MS optimum analysis conditions. Calibration blends were then prepared, and the self-consistency of the standard solutions and the calibration blends was tested through a comparison of response factors. The one blend that showed a representative value and good reproducibility among the blends was selected as the calibration standard blend. The LC/MS/MS run for the tyrosine measurements was repeated 5 times for all of the calibration blends and samples.
The concentration of tyrosine in the serum, C, determined by the ID-LC/MS/MS, was calculated by the following formula:
where Mis-tyr,spiked is the weight of the 4-hydroxyphenyl-13 C6-
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alanine solution spiked in the sample, Mtyr,std is the weight of the tyrosine standard solution applied to the calibration blend, Mis-tyr,std is the weight of the 4-hydroxyphenyl-13 C6-alanine solution applied to the calibration blend, Ctyr,std is the concentration of the tyrosine standard solution (μg/g), Ws is the weight of the sample, ARsample is the area ratio between the tyrosine and the 4-hydroxyphenyl-13 C6-alanine obtained from the LC/MS/MS measurement of the sample, and ARstd is the area ratio between the tyrosine and the 4-hydroxyphenyl-13 C6-alanine obtained from the LC/MS/MS measurement of the calibration blend.
Results and Discussion
In order to achieve the highest level of accuracy, it is necessary to obtain the proper mass chromatograms for quantification. The optimum conditions obtained from the tuning were used to obtain the mass chromatograms of the serum sample. Figure 1 shows the selected ion chromatograms of tyrosine and 4-hydroxyphenyl-13 C6-alanine molecular ion in serum at m/z 182.19 and 188.19, respectively. Tyrosine and 4-hydroxyphenyl-13 C6-alanine showed identical retention times. The chromatogram of tyrosine showed a proper peak shape, but the chromatogram of 4-hydroxyphenyl-13 C6-alanine showed a number of unbeneficial interfering peaks for quantification in SIM mode. In order to obtain more proper mass chromatogram, the MRM mode was attempted. Figure 2 shows MS/MS chromatograms of tyrosine and 4-hydroxyphenyl-13 C6-alanine in serum. As there was no significant interfering peak in the serum matrix, the MRM mode was selected for the quantification of tyrosine in the serum.
The isotopic interferences of the serum were also checked. Figure 3 shows the mass chromatograms of pure serum. It was possible to identify that the isotopically labeled analogue was not included in the serum sample. In order to use the exact signal matching method, we estimated the tyrosine concentration in the serum through a preliminary test. This was carried out by one point calibration.
The estimated concentration of tyrosine in the serum was determined to be 15 μg/g approximately.
In order to check the limit of detection (LOD), we diluted the serum tyrosine with mobile phase to 0.6 nmol/L, and we analyzed the sample 10 times repeatedly. The injection volume was 10 μL. LOD for tyrosine was approximately 1 nmol/L. For the quantitative analysis by IDMS, it is desirable that the signal-to-noise ratio should be at least 10:1.
As the accuracy of this method is determined by the reproducibility of the area ratio between tyrosine and 4-hydroxyphenyl-13 C6-alanine, the reproducibility of the measurement can serve as a performance parameter that verifies the method is adequate as a reference method. To test the reproducibility, we measured the spiked serum samples and a calibration blend repeatedly by LC/MS/MS. A long-term stabilization period is necessary in order to achieve the highest precision. The area ratios between the tyrosine and 4-hydroxyphenyl-13 C6-alanine in repeated measurements of the samples and the calibration blend showed no detectable longterm drifts or short-term fluctuations. The relative standard deviations of the ratios ranged from 0.4 to 0.8%, indicating that the method has good reproducibility.
The standard solutions and calibration blends must be verified to ensure that the IDMS results are traceable to the SI units, as the standard solutions are a direct reference to the IDMS results. Four calibration blends were tested under identical analytical conditions to those used in the sample analysis. The ratios of the peak area between tyrosine and 4-hydroxyphenyl-13 C6-alanine of each calibration blend were normalized by their weight ratios. The normalized area ratios of the 4 calibration blends agreed within 0.09%, as shown in Table 1 . This 301 ANALYTICAL SCIENCES MARCH 2007, VOL. 23 indicates that there were no mistakes during the preparation of the standard solutions and calibration blends. Among these calibration blends, the blend that had the closest value to the average value and that showed good reproducibility was selected as the standard solution for calibration.
Following this, the concentration of the tyrosine in the human serum was measured using this method. Five samples from one bottle were taken, and measurements were independently repeated 4 times. The entire measurement process, including the preparation and verification of a new set of standard solutions and calibration blends, as well as the sample preparation and LC/MS/MS analysis, was carried out independently for each measurement. Table 2 shows the measurement results for tyrosine in the human serum using the isotopically labeled analogue solution prepared with 0.1 N HCl. The serum samples were 5 for each measurement. The standard deviations within a single measurement were very low, but the standard deviation for several measurements was relatively high. This indicates that the 0.1 N HCl solvent can lead to the formation or degradation of proteins or peptides in the serum and then can change concentration of tyrosine. In order to solve this problem, we prepared an isotopically labeled analogue solution with water instead of 0.1 N HCl as a solvent, and 5 serum bottles were tested from the batch. When the isotopically labeled analogue solution prepared with water was used, the relative standard deviation of the result decreased to 0.35%, as shown in Table 3 . This indicated that the homogeneity between samples is good and that this method has a high degree of reproducibility. The expanded uncertainty of the result was evaluated by a program for uncertainty calculations through measurements and an analysis. It resulted in 0.14, which was appropriate as a reference method. In this study, a purity analysis of tyrosine was not performed. From the uncertainty budgeting, it was found that the area ratios between the tyrosine and 4-hydroxyphenyl-13 C6-alanine of the calibration blend and the serum sample were the main parameters contributing to the uncertainty. This indicates that the reproducibility of the measurement through instrumentation is the most important factor for reducing the uncertainty in this experiment.
Although it was proven that the candidate reference method is capable of making measurement results traceable to SI units, some degree of validation is always appropriate through the use of well-characterized standard or reference methods. The tyrosine of NIST SRM 2389 was measured by ID-LC/MS/MS. The certified value of the SRM is based on the results obtained from NIST analytical determinations using HPLC in addition to a round-robin study comprised of 13 participants conducted with the cooperation of the Association of Biomolecular Research Facilities (ABRF). Table 4 shows the certification value and the results of the measurement. The result with ID-LC/MS/MS agreed well with the gravimetric value and certification value, which was an average value of the results of the NIST measurement and the round-robin test. The result obtained from the ID-LC/MS/MS method showed less uncertainty in comparison with a certified value obtained by the HPLC method.
The serum samples were distributed to clinical laboratories that performed the analysis of amino acids in serum using an amino acid analyzer. The measurement results and expanded uncertainties were as follows: The measurement result of the ID-LC/MS/MS method was 14.30 ± 0.14 μg/g; the result of clinical laboratory A was 11.14 ± 0.50 μg/g and the result of clinical laboratory B was 17.15 ± 0.42 μg/g. There were inconsistent results among these clinical laboratories. This suggests that the use of well-characterized reference materials or reference methods is important in order that clinical laboratories may provide reliable results.
Conclusions
The ID-LC/MS/MS method is proposed as a candidate reference method for the determination of tyrosine in serum. The advantages of this method include a simple sample preparation without derivatization, the selective detection of compounds of interests in complex matrices, and the use of an isotopically labeled analogue as an internal standard. This method was applied in the determination of tyrosine in human serum. The expanded uncertainty of measurement results within a single sample were less than 1% within a 95% confidence level. The ID-LC/MS/MS result of NIST SRM was in good agreement with the certified value and showed a lower level of uncertainty compared to the certified value measured by the HPLC method. The measurement results of the serum tyrosine obtained from clinical laboratories were inconsistent. This suggests that the 302 ANALYTICAL SCIENCES MARCH 2007, VOL. 23 Table 1 Relative response factors of the calibration blends a. Weight of tyrosine/weight of 4-hydroxyphenyl-13 C6-alanine in calibration blend. b. Peak area of tyrosine/peak area of 4-hydroxyphenyl-13 C6-alanine. c. Peak area ratio/isotope ratio. 
